Malabre Richard C's Form 4 filing
Akebia Therapeutics, Inc.AKBA · filed Jun 5, 2025
- Accession no.
- 0001562180-25-004491
- Filed
- Jun 5, 2025
- Trade date
- Jun 4, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $47.1K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Malabre Richard CCIK 0002007730 | Officer (SVP, Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 4, 2025 | Common Stock | SSaleDisposed | −13,334 | $3.53F2 | −$47,069.02 | 266,914 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The shares were sold at prices ranging from $3.50 to $3.60 and the price reported reflects the weighted average sale price.
Referenced by the price of 1 transaction in Table I.